Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

References

• McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, Bennett NM, Scahill M, Niccolai LM, Brackney M, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women — United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68:337–10. doi:10.15585/mmwr.mm6815a1.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377:932–40. doi:10.1016/S0140-6736(10)62342-2.
   PubMed Web of Science ®Google Scholar
• Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, da Silva RJC, Baggio ML, Quiterio M, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res. 2012;72:676–85. doi:10.1158/0008-5472.CAN-11-0751.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Sirak B, Abrahamsen M, Silva RJC, Baggio ML, Galan L, Cintra RC, Lazcano-Ponce E, Villa LL. Genital wart recurrence among men residing in Brazil, Mexico, and the United States. J Infect Dis. 2019;219(5):703–10. doi:10.1093/infdis/jiy533.
   PubMed Web of Science ®Google Scholar
• Beachler DC, Pinto LA, Kemp TJ, Nyitray AG, Hildesheim A, Viscidi R, Schussler J, Kreimer AR, Giuliano AR. An examination of HPV16 natural immunity in men who have sex with men (MSM) in the HPV in men (HIM) study. Cancer Epidemiol Biomarkers Prev. 2018;27:496–502. doi:10.1158/1055-9965.EPI-17-0853.
   PubMed Web of Science ®Google Scholar
• Munoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57. doi:10.1016/S0140-6736(09)60691-7.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-Of-Study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105:28–37. doi:10.1038/bjc.2011.185.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, Quiterio M, Lazcano-Ponce E. Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—the MAM study. Vaccine. 2015;33:5640–46. doi:10.1016/j.vaccine.2015.08.072.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Faivre P, Lopalco PL, Joura EA, Bergroth T, Varga S, Gemayel N, Drury R. The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019). Expert Rev Vaccines. 2020;19:1073–83. doi:10.1080/14760584.2020.1858057.
   PubMed Web of Science ®Google Scholar
• Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: Updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68:698–702. doi:10.15585/mmwr.mm6832a3.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43. doi:10.1056/NEJMoa061760.
   PubMed Web of Science ®Google Scholar
• Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol. 2005;12:959–69. doi:10.1128/CDLI.12.8.959-969.2005.
   PubMedGoogle Scholar
• Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10:108–15.
   PubMedGoogle Scholar
• Smith JF, Kowalski R, Esser MT, Brown MJ, Bryan JT. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin. 2008;4:134–42. doi:10.4161/hv.4.2.5261.
   PubMedGoogle Scholar
• Opalka D, Matys K, Bojczuk P, Green T, Gesser R, Saah A, Haupt R, Dutko F, Esser MT. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol. 2010;17:818–27. doi:10.1128/CVI.00348-09.
   PubMedGoogle Scholar
• Saah A, Bautista O, Luxembourg A, Perez G. Intention-To-Prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies. Contemp Clin Trials Commun. 2017;7:189–93. doi:10.1016/j.conctc.2017.07.010.
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19:261–67. doi:10.1128/CVI.05208-11.
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagueé X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135–45. doi:10.1542/peds.2006-0461.
   PubMed Web of Science ®Google Scholar
• Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, Afsar OZ, LaMontagne DS, Mosina L, Contreras M, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399. doi:10.1016/j.ypmed.2020.106399.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Brown DR, Giuliano AR, Myers E, Joura EA, Garland SM, Kjaer SK, Perez G, Saah A, Luxembourg A, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res. 2020;10:100202. doi:10.1016/j.pvr.2020.100202.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Hseon Tay E, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccine. 2009;5:696–704. doi:10.4161/hv.5.10.9515.
   PubMed Web of Science ®Google Scholar
• Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;344(mar27 3):e1401. doi:10.1136/bmj.e1401.
   PubMedGoogle Scholar
• Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130:264–68. doi:10.1016/j.ygyno.2013.04.050.
   PubMed Web of Science ®Google Scholar
• Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow SN, Apter D, Castellsagué X, Teixeira JC, Skinner SR, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial. Int J Cancer. 2016;139:2812–26. doi:10.1002/ijc.30391.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154–68. doi:10.1016/S1473-3099(16)30120-7.
   PubMed Web of Science ®Google Scholar
• Ingles DJ, Lin HY, Fulp WJ, Sudenga SL, Lu B, Schabath MB, Papenfuss MR, Abrahamsen ME, Salmeron J, Villa LL, et al. An analysis of HPV infection incidence and clearance by genotype and age in men: the HPV infection in men (HIM) study. Papillomavirus Res. 2015;1:126–35. doi:10.1016/j.pvr.2015.09.001.
   PubMedGoogle Scholar
• Bautista OM, Saah A, Munoz NR. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2011;103:158–59.
   PubMedGoogle Scholar
• Skinner SR, Wheeler CM, Romanowski B, Castellsague X, Lazcano-Ponce E, Del Rosario-Raymundo MR, et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. Int J Cancer. 2016;138:2428–38.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, et al. 4-Valent human papillomavirus (4vhpv) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140:ii: e20163947.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClinicalMedicine. 2020;23:100401.
   PubMedGoogle Scholar
• Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13:119–32.
   PubMed Web of Science ®Google Scholar